Almirall and Forest's COPD drug positive in Phase III with new dosing
This article was originally published in Scrip
Executive Summary
Almirall and Forest Laboratories' long-acting muscarinic antagonist (LAMA) Eklira (aclidinium bromide) has met its primary endpoint in the Phase III ACCORD COPD I study, which tested a new twice-daily dose. Investors were largely unmoved by the news, however, perhaps because Eklira disappointed in two previous Phase III studies.